PLATFORM TECHNOLOGY DEFINED
Platform Technology Defined
This update is specifically targeted towards the understanding of Platform Technology. It is used in various ways within the scientific and medical industries, and we believe it is important to define our specific use of this terminology as it pertains to our technology.
RP-323, is a small molecule drug which can potentially treat a number of diseases, allowing us to expand our pipeline without the need of new drug discoveries. If you have been following our campaign, you may have seen this when we addressed the COVID-19 crisis. This ability of our single compound, RP-323, to treat multiple diseases is the reason for its classification as a Platform Technology. This capability for multiple uses can allow us to increase the pipeline, potentially creating a dominant intellectual property position, offering multiple shots at end target and possible increased future revenues.
Over the course of our campaign, we have received and responded to several questions asking if we intend to address specific diseases and medical challenges which are not in our current pipeline, which presently includes COVID-19, Acute Myeloid Leukemia, Hodgkin’s Lymphoma, and Parkinson’s disease. These comments have included requests for targeting amyotrophic lateral sclerosis (ALS), prostate cancers, human immunodeficiency virus (HIV), and even ageing. As a company, it is our sincere hope that additional indications could be added to our pipeline in the future as the stories we receive from people who suffer from disease directly, or through family and friends, are continual reminders of why we became involved in this business.
PhorMed continues to strive towards the development of treatment options that will offer hope to those who suffer from diseases with few other options.
We would like to thank all our current and new investors, and all the people who have followed our campaign. For those who have already invested, we thank you. If you have not yet invested in PhorMed, please consider investing now to join us on this journey forward.
Thank you all and be well,
Vice President of Marketing & Business Development